Do analysts recommend UNCY or LTRN?

Unicycive Therapeutics presently has a consensus price target of $21.75, suggesting a potential upside of 302.78%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Unicycive Therapeutics is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Unicycive Therapeutics 2 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.43 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is UNCY or LTRN more profitable?

Unicycive Therapeutics' return on equity of -134.69% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Unicycive Therapeutics N/A -134.69% -84.51% Lantern Pharma N/A -198.34% -129.08%

Does the media refer more to UNCY or LTRN?

In the previous week, Unicycive Therapeutics had 2 more articles in the media than Lantern Pharma. MarketBeat recorded 4 mentions for Unicycive Therapeutics and 2 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.93 beat Unicycive Therapeutics' score of 0.56 indicating that Lantern Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend MIST or LTRN?

Milestone Pharmaceuticals currently has a consensus target price of $7.25, suggesting a potential upside of 525.00%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Milestone Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MIST or LTRN more profitable?

Lantern Pharma's return on equity of -198.34% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Milestone Pharmaceuticals N/A -339.33% -61.79% Lantern Pharma N/A -198.34% -129.08%

Do analysts prefer HUMA or LTRN?

Humacyte presently has a consensus price target of $6.25, suggesting a potential upside of 900.32%. Given Humacyte's stronger consensus rating and higher possible upside, analysts plainly believe Humacyte is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Humacyte 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HUMA or LTRN more profitable?

Lantern Pharma has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. Lantern Pharma's return on equity of -198.34% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Humacyte -4,836.06% -2,914.18% -89.45% Lantern Pharma N/A -198.34% -129.08%

Does the media refer more to HUMA or LTRN?

In the previous week, Humacyte and Humacyte both had 2 articles in the media. Lantern Pharma's average media sentiment score of 0.93 beat Humacyte's score of 0.48 indicating that Lantern Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Humacyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer NGEN or LTRN?

NervGen Pharma presently has a consensus target price of $14.00, indicating a potential upside of 758.90%. Given NervGen Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe NervGen Pharma is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NervGen Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 2.83 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, NGEN or LTRN?

NervGen Pharma is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NervGen Pharma N/A N/A N/A -$0.09 N/A Lantern Pharma N/A N/A -$17.12M -$1.45 N/A

Is NGEN or LTRN more profitable?

NervGen Pharma's return on equity of 0.00% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets NervGen Pharma N/A N/A N/A Lantern Pharma N/A -198.34% -129.08%

Does the media refer more to NGEN or LTRN?

In the previous week, NervGen Pharma had 1 more articles in the media than Lantern Pharma. MarketBeat recorded 3 mentions for NervGen Pharma and 2 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.93 beat NervGen Pharma's score of 0.62 indicating that Lantern Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NervGen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate LTRN or HURA?

TuHURA Biosciences has a consensus target price of $9.00, suggesting a potential upside of 326.54%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe TuHURA Biosciences is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TuHURA Biosciences 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has better earnings & valuation, LTRN or HURA?

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantern Pharma N/A N/A -$17.12M -$1.45 N/A TuHURA Biosciences N/A N/A -$30.05M -$0.61 N/A

Is LTRN or HURA more profitable?

TuHURA Biosciences' return on equity of -156.12% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lantern Pharma N/A -198.34% -129.08% TuHURA Biosciences N/A -156.12% -105.38%

Does the media favor LTRN or HURA?

In the previous week, TuHURA Biosciences had 3 more articles in the media than Lantern Pharma. MarketBeat recorded 5 mentions for TuHURA Biosciences and 2 mentions for Lantern Pharma. TuHURA Biosciences' average media sentiment score of 0.94 beat Lantern Pharma's score of 0.93 indicating that TuHURA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TuHURA Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lantern Pharma (LTRN) Competitors

$2.75 -0.12 (-4.18%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$2.89 +0.14 (+5.09%)

As of 07/24/2026 04:53 PM Eastern

Compare

LTRN vs. UNCY, MIST, HUMA, NGEN, and HURA

Should you buy Lantern Pharma stock or one of its competitors? MarketBeat compares Lantern Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lantern Pharma include Unicycive Therapeutics (UNCY), Milestone Pharmaceuticals (MIST), Humacyte (HUMA), NervGen Pharma (NGEN), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry.

How does Lantern Pharma compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

In the previous week, Unicycive Therapeutics had 2 more articles in the media than Lantern Pharma. MarketBeat recorded 4 mentions for Unicycive Therapeutics and 2 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.93 beat Unicycive Therapeutics' score of 0.56 indicating that Lantern Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantern Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Unicycive Therapeutics presently has a consensus price target of $21.75, suggesting a potential upside of 302.78%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Unicycive Therapeutics is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Lantern Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Unicycive Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.3, indicating that its stock price is 130% more volatile than the broader market.

Unicycive Therapeutics' return on equity of -134.69% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
Lantern Pharma	N/A	-198.34%	-129.08%

Lantern Pharma has lower revenue, but higher earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	217.51	-$26.56M	-$2.21	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A

Summary

Unicycive Therapeutics beats Lantern Pharma on 8 of the 14 factors compared between the two stocks.

How does Lantern Pharma compare to Milestone Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

Lantern Pharma's return on equity of -198.34% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%
Lantern Pharma	N/A	-198.34%	-129.08%

Milestone Pharmaceuticals has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.3, indicating that its share price is 130% more volatile than the broader market.

Milestone Pharmaceuticals currently has a consensus target price of $7.25, suggesting a potential upside of 525.00%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Lantern Pharma had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 2 mentions for Lantern Pharma and 1 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 1.87 beat Lantern Pharma's score of 0.93 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Milestone Pharmaceuticals	Very Positive
Lantern Pharma	Positive

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 8.5% of Lantern Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Lantern Pharma has lower revenue, but higher earnings than Milestone Pharmaceuticals. Lantern Pharma is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.78M	80.95	-$63.06M	-$0.68	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A

Summary

Milestone Pharmaceuticals beats Lantern Pharma on 10 of the 15 factors compared between the two stocks.

How does Lantern Pharma compare to Humacyte?

Humacyte (NASDAQ:HUMA) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, Humacyte and Humacyte both had 2 articles in the media. Lantern Pharma's average media sentiment score of 0.93 beat Humacyte's score of 0.48 indicating that Lantern Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Humacyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantern Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Humacyte has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.3, indicating that its share price is 130% more volatile than the broader market.

44.7% of Humacyte shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 3.1% of Humacyte shares are owned by company insiders. Comparatively, 8.5% of Lantern Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lantern Pharma has lower revenue, but higher earnings than Humacyte. Lantern Pharma is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Humacyte	$2.02M	68.81	-$40.83M	-$0.57	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A

Humacyte presently has a consensus price target of $6.25, suggesting a potential upside of 900.32%. Given Humacyte's stronger consensus rating and higher possible upside, analysts plainly believe Humacyte is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lantern Pharma has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. Lantern Pharma's return on equity of -198.34% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Humacyte	-4,836.06%	-2,914.18%	-89.45%
Lantern Pharma	N/A	-198.34%	-129.08%

Summary

Humacyte beats Lantern Pharma on 9 of the 14 factors compared between the two stocks.

How does Lantern Pharma compare to NervGen Pharma?

NervGen Pharma (NASDAQ:NGEN) and Lantern Pharma (NASDAQ:LTRN) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

In the previous week, NervGen Pharma had 1 more articles in the media than Lantern Pharma. MarketBeat recorded 3 mentions for NervGen Pharma and 2 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.93 beat NervGen Pharma's score of 0.62 indicating that Lantern Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantern Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NervGen Pharma is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	N/A	-$0.09	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A

NervGen Pharma presently has a consensus target price of $14.00, indicating a potential upside of 758.90%. Given NervGen Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe NervGen Pharma is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NervGen Pharma's return on equity of 0.00% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	N/A	N/A
Lantern Pharma	N/A	-198.34%	-129.08%

28.6% of Lantern Pharma shares are held by institutional investors. 5.8% of NervGen Pharma shares are held by insiders. Comparatively, 8.5% of Lantern Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

NervGen Pharma beats Lantern Pharma on 8 of the 12 factors compared between the two stocks.

How does Lantern Pharma compare to TuHURA Biosciences?

Lantern Pharma (NASDAQ:LTRN) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

TuHURA Biosciences has a consensus target price of $9.00, suggesting a potential upside of 326.54%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe TuHURA Biosciences is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, TuHURA Biosciences had 3 more articles in the media than Lantern Pharma. MarketBeat recorded 5 mentions for TuHURA Biosciences and 2 mentions for Lantern Pharma. TuHURA Biosciences' average media sentiment score of 0.94 beat Lantern Pharma's score of 0.93 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantern Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TuHURA Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TuHURA Biosciences' return on equity of -156.12% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-198.34%	-129.08%
TuHURA Biosciences	N/A	-156.12%	-105.38%

28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 8.5% of Lantern Pharma shares are held by company insiders. Comparatively, 6.1% of TuHURA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A

Lantern Pharma has a beta of 2.3, indicating that its share price is 130% more volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.05, indicating that its share price is 105% less volatile than the broader market.

Summary

TuHURA Biosciences beats Lantern Pharma on 8 of the 13 factors compared between the two stocks.

Get Lantern Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LTRN vs. The Competition

Export

Metric	Lantern Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$36.62M	$3.68B	$6.88B	$12.28B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-1.90	21.29	27.08	23.71
Price / Sales	N/A	161.60	495.86	74.92
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	4.74	7.88	10.28	6.07
Net Income	-$17.12M	$23.86M	$3.60B	$331.99M
7 Day Performance	-4.18%	-3.82%	-1.27%	-0.63%
1 Month Performance	-25.07%	-2.61%	-0.36%	-2.00%
1 Year Performance	-35.14%	32.79%	18.31%	13.62%

Lantern Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LTRN Lantern Pharma	0.5416 of 5 stars	$2.75 -4.2%	N/A	-35.4%	$36.62M	N/A	N/A	20	News Coverage
UNCY Unicycive Therapeutics	3.0249 of 5 stars	$5.69 +4.4%	$21.75 +282.2%	+11.3%	$149.29M	$680K	N/A	9	Analyst Downgrade
MIST Milestone Pharmaceuticals	2.2445 of 5 stars	$1.23 +4.2%	$7.25 +489.4%	-26.1%	$146.91M	$1.55M	N/A	30	Positive News
HUMA Humacyte	3.4184 of 5 stars	$0.67 +2.2%	$6.25 +831.7%	-76.6%	$145.69M	$2.04M	N/A	150
NGEN NervGen Pharma	2.3436 of 5 stars	$1.78 +2.9%	$14.00 +686.5%	N/A	$143.52M	N/A	N/A	N/A	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LTRN) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lantern Pharma (LTRN) Competitors

LTRN vs. UNCY, MIST, HUMA, NGEN, and HURA

How does Lantern Pharma compare to Unicycive Therapeutics?

Summary

How does Lantern Pharma compare to Milestone Pharmaceuticals?

Summary

How does Lantern Pharma compare to Humacyte?

Summary

How does Lantern Pharma compare to NervGen Pharma?

Summary

How does Lantern Pharma compare to TuHURA Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LTRN vs. The Competition

Lantern Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lantern Pharma (LTRN) Competitors

LTRN vs. UNCY, MIST, HUMA, NGEN, and HURA

How does Lantern Pharma compare to Unicycive Therapeutics?

Does the media refer more to UNCY or LTRN?

Do analysts recommend UNCY or LTRN?

Do institutionals and insiders have more ownership in UNCY or LTRN?

Which has more risk and volatility, UNCY or LTRN?

Is UNCY or LTRN more profitable?

Which has stronger valuation and earnings, UNCY or LTRN?

Summary

How does Lantern Pharma compare to Milestone Pharmaceuticals?

Is MIST or LTRN more profitable?

Which has more volatility and risk, MIST or LTRN?

Do analysts recommend MIST or LTRN?

Does the media refer more to MIST or LTRN?

Do institutionals & insiders have more ownership in MIST or LTRN?

Which has better earnings & valuation, MIST or LTRN?

Summary

How does Lantern Pharma compare to Humacyte?

Does the media refer more to HUMA or LTRN?

Which has more risk & volatility, HUMA or LTRN?

Do institutionals and insiders have more ownership in HUMA or LTRN?

Which has higher valuation & earnings, HUMA or LTRN?

Do analysts prefer HUMA or LTRN?

Is HUMA or LTRN more profitable?

Summary

How does Lantern Pharma compare to NervGen Pharma?

Does the media refer more to NGEN or LTRN?

Which has better earnings and valuation, NGEN or LTRN?

Do analysts prefer NGEN or LTRN?

Is NGEN or LTRN more profitable?

Do institutionals and insiders believe in NGEN or LTRN?

Summary

How does Lantern Pharma compare to TuHURA Biosciences?

Do analysts rate LTRN or HURA?

Does the media favor LTRN or HURA?

Is LTRN or HURA more profitable?

Do institutionals and insiders believe in LTRN or HURA?

Which has better earnings & valuation, LTRN or HURA?

Which has more risk & volatility, LTRN or HURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LTRN vs. The Competition

Lantern Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools